Optimizing leukapheresis product yield and purity for blood cell-based gene and immune effector cell therapy
PA Shi - Current Opinion in Hematology, 2020 - journals.lww.com
Optimizing leukapheresis product yield and purity for blood... : Current Opinion in Hematology
Optimizing leukapheresis product yield and purity for blood cell-based gene and immune effector …
Optimizing leukapheresis product yield and purity for blood cell-based gene and immune effector …
Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients
A Jarisch, E Rettinger, J Sörensen… - Journal of Clinical …, 2020 - Wiley Online Library
Autologous unstimulated leukapheresis product serves as starting material for a variety of
innovative cell therapy products, including chimeric antigen receptor (CAR)‐modified T …
innovative cell therapy products, including chimeric antigen receptor (CAR)‐modified T …
Potentially modifiable predictors of cell collection efficiencies and product characteristics of allogeneic hematopoietic progenitor cell collections
HP Pham, S Dormesy, K Wolfe, A Budhai… - …, 2021 - Wiley Online Library
Background Hematopoietic progenitor cell (HPC) and immune effector cell (IEC) therapies
often require high doses of mononuclear cells (MNCs), whether CD34+ cells, lymphocytes …
often require high doses of mononuclear cells (MNCs), whether CD34+ cells, lymphocytes …
Effective peripheral blood stem cell collection in a 4.6‐kg child
JM Jones, JE Kiss, I Chibisov, P Horvei… - …, 2024 - Wiley Online Library
Background Due to unique technical challenges, effective peripheral blood stem cell
collections (PBSCs) have not been consistently reported in patients weighing less than 5 kg …
collections (PBSCs) have not been consistently reported in patients weighing less than 5 kg …
Cytaphérèses pédiatriques (SFGM-TC)
C Chabannon, M Benakli, K Alexandrova, C Coze… - Bulletin du …, 2025 - Elsevier
Practice of pediatric aphereses–in particular when caring for low-weight children–differs
from the practice of adult aphereses, since pediatric aphereses represent low numbers of …
from the practice of adult aphereses, since pediatric aphereses represent low numbers of …
[HTML][HTML] Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an italian expert Panel
G Leone, V Baldini, S Bramanti, R Crocchiolo… - Blood …, 2023 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T-cell therapy relies on T cells engineered to target specific
tumor antigens such as CD-19 in B-cell malignancies. In this setting, the commercially …
tumor antigens such as CD-19 in B-cell malignancies. In this setting, the commercially …
Role of therapeutic apheresis in the treatment of pediatric kidney diseases
S Shah, C Joseph, P Srivaths - Pediatric Nephrology, 2022 - Springer
Therapeutic apheresis utilizes apheresis procedures in the treatment of a variety of
conditions including kidney disease. Therapeutic plasma exchange (TPE) is the most …
conditions including kidney disease. Therapeutic plasma exchange (TPE) is the most …
Report of plasma exchange in a rare case of association of myasthenia gravis with thymoma and parathyroid adenoma
N Prinja, G Siwach, S Aleti, R Hans… - Asian Journal of …, 2022 - journals.lww.com
Report of plasma exchange in a rare case of association of m... : Asian Journal of Transfusion
Science Report of plasma exchange in a rare case of association of myasthenia gravis with …
Science Report of plasma exchange in a rare case of association of myasthenia gravis with …
[引用][C] Using CD19 chimeric antigen receptor‐T cell therapy in a 4‐month‐old patient with infantile acute lymphoblastic leukemia
DC Shyr, AA Homsombath, PP Chan… - Pediatric Blood & …, 2020 - Wiley Online Library